Pharmacokinetics of altrenogest in gilts.

Hongzhi Xiao,Pan Sun,Feifei Sun,Jicheng Qiu,Jie Wang,Jianzhong Wang,Yalong Lin,Xiaohui Gong,Lu Zhang,Suxia Zhang,Xingyuan Cao
DOI: https://doi.org/10.1111/jvp.12755
IF: 1.567
2019-01-01
Journal of Veterinary Pharmacology and Therapeutics
Abstract:Altrenogest, a synthetic progestogen, is characterized by its estrus synchronization in mares, ewes, sows, and gilts. To investigate the pharmacokinetic profile and evaluate its accumulation in gilts, 18 oral doses of 20 mg altrenogest/gilt/day were given to eight healthy gilts at an interval of 24 hr. Plasma samples were collected, and altrenogest was determined by ultra-high-performance liquid chromatography with mass spectrometry. WinNonlin 6.4 software was used to calculate the pharmacokinetic parameters through noncompartmental model analysis. After the first administration (D 1), the pharmacokinetic parameters, including T-max, C-max, and the elimination half-life (T-1/2 lambda z), were similar to those observed after the final administration (D 18). However, the mean residence time at D 1 was significantly lower than D 18. As a whole, the mean steady-state plasma concentration (C-ss), degree fluctuation (DF), accumulation factor (R-ac), and area under the plasma concentration-time curve in steady state (AUC(ss)) were 22.69 +/- 6.15 ng/ml, 270.64 +/- 42.51%, 1.53 +/- 0.23, and 544.63 +/- 147.49 ng hr/ml, respectively. These results showed that after 18 consecutive days of oral administration of altrenogest, plasma concentrations of altrenogest had a certain degree of fluctuation, without significant accumulations.
What problem does this paper attempt to address?